Latest news with #HUMA
Business Insider
04-07-2025
- Business
- Business Insider
BTCC Exchange Reports Remarkable Q2 2025 Performance with $957 Billion Trading Volume
BTCC, one of the world's longest-operating cryptocurrency exchanges, today announced exceptional Q2 results for 2025, with total trading volume surpassing $957 billion and user base expanding to over 9.1 million globally. The milestone quarter was highlighted by BTCC's 14th anniversary celebration in June. Q2 Trading Volumes Surge with Strategic Product Expansion BTCC's remarkable $957 billion total trading volume comprised $107 billion in spot trading and $850 billion in futures trading, representing substantial growth from Q1's $815 billion. The exchange strategically expanded its futures offerings by listing trending coins, including HUMA (Huma Finance), PLUME (Plume), and RESOLV (Resolv), while breaking new ground in tokenized assets by adding POPMART tokenized stock, a booming Hong Kong-listed company famous for its viral Labubu collectibles. "Q2 2025 showed the resilience and maturity of both our platform and the broader crypto ecosystem," said Alex Hung, Head of Operations at BTCC. "Even with market fluctuations, we achieved exceptional performance with over 9.1 million registered users now trusting our platform while staying committed to user protection." Beyond trading volume growth, BTCC reinforced its commitment to user safety by strengthening its Risk Reserve Fund with an additional $1.8 million, bringing the total to over $16.8 million. Enhanced Transparency with Monthly Proof of Reserves Reports In addition to strengthening security measures, BTCC took a major step forward in transparency by releasing monthly Proof of Reserves reports throughout Q2. The total reserve ratio across major currencies, including BTC, ETH, XRP, USDT, USDC, and ADA, consistently exceeded industry standards, with April reaching 161%, May maintaining 152%, and June achieving 135% — all significantly above the 100% industry benchmark. Upgraded Demo Feature and Anniversary Milestone Complementing its transparency efforts, BTCC enhanced its beginner-friendly platform with an upgraded demo trading feature that allows users to self-service top-ups of up to 500,000 USDT per week for expanded practice trading opportunities. Building on these user-focused improvements, June 2025 marked BTCC's 14th anniversary, a milestone celebrated with the launch of the platform's first-ever user badge program featuring the exclusive "14 Years of Momentum" badge. Badge holders can enjoy ongoing exclusive benefits, including airdrops, special campaigns, and community recognition. "Our 14th anniversary celebration was particularly meaningful as it honored users who have trusted us through various market cycles," said Alex Hung. "The badge program is our way of giving back to the community that has been with us on this incredible journey." Global Community Engagement Takes Center Stage Extending beyond the platform, BTCC brought the crypto community together offline with a major presence at TOKEN2049 Dubai as gold sponsor in April, hosting an exclusive desert safari tour and a VIP yacht party featuring top crypto influencers. The exchange also demonstrated its commitment to social responsibility by partnering with Red Eagle Foundation to facilitate Bitcoin donations at the Legends Golf Day charity event in April. Strategic Roadmap for Continued Excellence Building on Q2's achievements, BTCC plans to launch a comprehensive Trading Info Center in Q3, with the Quick Updates section going live in July. The exchange is also advancing its Futures Pro platform, currently in beta, with plans to roll out additional features and system optimizations. "Our upcoming Trading Info Center represents our commitment to user-centric services, providing users with the tools they need to navigate this dynamic market successfully," said Alex Hung. "As we enter the second half of 2025, BTCC remains committed to platform enhancement while maintaining the trust and security standards that have defined our 14-year journey." Looking ahead, BTCC is preparing for major community engagement initiatives, including an offline summer festival in Japan and a strategic athlete sponsorship scheduled for August 2025. As BTCC continues to evolve and adapt to the changing cryptocurrency landscape, the exchange remains steadfast in its mission to provide secure, reliable trading services that aim to empower users to succeed in their crypto trading journey. About BTCC Founded in 2011, BTCC is one of the world's longest-serving cryptocurrency exchanges, offering secure and user-friendly trading services to millions of users globally. With a commitment to security, innovation, and community building, BTCC continues to be a trusted platform in the evolving cryptocurrency landscape. Contact Aaryn Ling
Yahoo
26-06-2025
- Business
- Yahoo
Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know
In the latest close session, Humacyte, Inc. (HUMA) was down 1.79% at $2.19. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%. The company's stock has dropped by 10.08% in the past month, falling short of the Medical sector's gain of 3.46% and the S&P 500's gain of 5.05%. The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. On that day, Humacyte, Inc. is projected to report earnings of -$0.15 per share, which would represent year-over-year growth of 44.44%. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.18 per share and a revenue of $8.77 million, representing changes of +82.86% and 0%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Humacyte, Inc. is holding a Zacks Rank of #2 (Buy) right now. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 34% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Cision Canada
09-06-2025
- Business
- Cision Canada
MEXC Hits 40M Users with 46% Growth in New Listing Token Trading Volume in May
VICTORIA, Seychelles, June 9, 2025 /CNW/ -- MEXC, a leading global cryptocurrency exchange, has released its May 2025 performance update, showcasing another strong month of growth across user acquisition, trading activity, and sectoral momentum. The platform's global user base surpassed 40 million, up from 30 million in December 2024 — a 33% increase in just five months. Key Highlights: Listing Activity and Trading Volume Growth MEXC listed 214 new tokens in May, marking one of the most active listing months to date. Trading volume tied to these listings jumped by 46.7%, while average trading volume per user increased by 45.09% — signaling rising user engagement and growing confidence in MEXC's early-stage project selection. MEXC's total daily trading volume reached $4.1 billion according to CoinMarketCap, making it the second-largest platform by trading volume among leading crypto exchanges. Sector Momentum: AI, GameFi, Meme Coins Some of the strongest gains came from sectors that continue to define the next market cycle. AI infrastructure token AGT posted a peak gain of +3,770.10%, followed closely by blockchain gaming project NXPC (+3,756.30%) and PayFi protocol HUMA (+1,170.00%). Meme coins remained a major force in May, with retail-driven tokens from Solana and BNB Chain dominating charts. GOONC surged +3,400%, B gained +3,001.20%, and MOONPIG rallied +753.33%, demonstrating the power of meme communities in driving liquidity and excitement. User Incentives: Airdrops and Launchpools May also marked a record month for user rewards and event participation. MEXC hosted 58 Airdrop+ campaigns, more than doubling the number from April. The combined prize pool exceeded 3 million USDT, attracting nearly 40,000 users. Campaigns like AIOT (7,000+ participants, ~320 USDT value per user) and HUMA (100 USDT in tokens, followed by a 1,170% gain) stood out for their strong user response and post-listing performance. Launchpool events continued to deliver high returns. The ICEBERG pool offered an 8,488.44% APR, while the ongoing EIN Launchpool, open until July 17, remains attractive due to its high rewards and relatively low participation. Looking Ahead With momentum across listings, incentives, and user growth, MEXC continues to strengthen its position as a global launchpad for high-potential tokens. Strategic focus remains on trending verticals such as AI, Real World Assets (RWA), GameFi, and the TON ecosystem, where user demand and innovation are converging. About MEXC Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
Business Insider
07-06-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Buy Rating on Humacyte (HUMA)
TD Cowen analyst Josh Jennings maintained a Buy rating on Humacyte (HUMA – Research Report) today. The company's shares opened today at $2.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Jennings is a 4-star analyst with an average return of 4.6% and a 52.11% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. Humacyte has an analyst consensus of Strong Buy, with a price target consensus of $11.20. Based on Humacyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $517 thousand and a net profit of $39.14 million. In comparison, last year the company had a GAAP net loss of $31.9 million Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HUMA in relation to earlier this year. Most recently, in April 2025, William John Scheessele, the CCO of HUMA bought 6,493.00 shares for a total of $9,999.22.
Yahoo
14-05-2025
- Business
- Yahoo
Humacyte Inc (HUMA) Q1 2025 Earnings Call Highlights: A Turnaround with Symvess Launch and ...
Revenue: $517,000 for Q1 2025, including $147,000 from the US commercial launch of Symvess. Cost of Goods Sold: $147,000 for Q1 2025. Research and Development Expenses: $15.4 million for Q1 2025, down from $21.3 million in Q1 2024. General and Administrative Expenses: $8.1 million for Q1 2025, up from $5.3 million in Q1 2024. Other Net Income: $62.3 million for Q1 2025, compared to a net expense of $5.3 million in Q1 2024. Net Income: $39.1 million for Q1 2025, compared to a net loss of $31.9 million in Q1 2024. Cash, Cash Equivalents, and Restricted Cash: $113.2 million as of March 31, 2025. Net Cash Provided: $17.9 million for the first three months of 2025. Workforce Reduction: Approximately 31 employees, with estimated savings of $13.8 million in 2025 and up to $38 million in 2026. Warning! GuruFocus has detected 2 Warning Signs with HUMA. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Humacyte Inc (NASDAQ:HUMA) successfully launched Symvess, a groundbreaking product for extremity vascular trauma, with initial shipments to three Level 1 trauma centers. The company has extended its cash runway through recent financing and cost reductions, allowing for aggressive expansion of its commercial launch. Symvess has been approved by the Value Analysis Committees (VACs) of five hospitals, with 45 hospitals currently evaluating the product. The publication of a Budget Impact Model in the Journal of Medical Economics demonstrates Symvess's economic value by reducing infections and amputations. Humacyte Inc (NASDAQ:HUMA) is making progress in the military market, with multiple military treatment facilities expressing interest in purchasing Symvess. The company faced unfounded negative press regarding Symvess, which created some headwinds in the VAC approval process. A reduction in workforce by approximately 31 employees was implemented to extend the cash runway, indicating financial constraints. The volatile economic environment poses challenges to the commercial launch and expansion efforts. The New York Times article created some pushback from VACs, requiring additional efforts to address concerns. The process for VAC approvals and sales is expected to be lengthy, with most sales anticipated in the second half of the year. Q: Can you provide insights into the experience of the three sites that have purchased Symvess and how the VAC process is progressing? A: Dr. Laura Niklason, President and CEO, explained that the first implant was successful, with sales reps present at some sites. The VAC approval process is progressing well, despite some initial setbacks due to negative press. BJ Scheessele, Chief Commercial Officer, added that the sales funnel is strong, with 45 submissions and five approvals, and they expect momentum to build in the second half of the year. Q: How does the ECAT process work for military and federal hospitals, and are there additional hurdles? A: Dr. Laura Niklason stated that once Symvess is listed on ECAT, military hospitals can order it, but surgeon champions are crucial. BJ Scheessele noted that they are working with a DoD procurement partner to facilitate the process, and military hospitals typically do not have a formal VAC process. Q: Are current sales force levels sufficient to cover military hospitals and Level 1 trauma centers? A: BJ Scheessele confirmed that the current sales force is adequate to cover existing targets and that they will consider expanding the team as success grows in both civilian and military markets. Q: Do current revenue estimates for 2025 remain reasonable given recent progress? A: Dale Sander, CFO, confirmed that they are comfortable with the guidance provided earlier, expecting most revenues to come in the second half of the year due to the VAC process. Q: What learnings from previous Phase III studies are being applied to the V012 trial? A: Dr. Laura Niklason highlighted the importance of managing the conduit in dialysis centers and ensuring adherence to clinical protocols. They are focusing on patient subgroups that struggle with fistulas, anticipating positive trial results. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
